Market Currents
Baxter International (BAX) captures FDA approval for routine prophylaxis of its Advate...
-
Friday, December 16, 2011, 9:30 AM ETBaxter International (BAX) captures FDA approval for routine prophylaxis of its Advate hemophilia treatment after showing positive results in a Phase IV study.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
